Pasireotide Peptide: Signifor, Cushing's Disease and Acromegaly

Pasireotide is a peptide drug with a very different evidence profile from research-market peptides. It is a synthetic, multi-receptor somatostatin analog, first known by the development code SOM230, sold as Signifor for subcutaneous injection and Signifor LAR as a long-acting intramuscular depot. Novartis developed it, and it carries genuine US Food and Drug Administration labels for two pituitary-driven hormone disorders.

The headline feature is receptor breadth. Older somatostatin analogs such as octreotide and lanreotide are biased toward somatostatin receptor subtype 2. Pasireotide binds a wider profile, with especially high affinity for subtype 5, which is the rationale for using it in conditions where subtype-2-preferential drugs fall short. That same breadth also drives its most important side effect.

This guide is educational and not medical advice. Pasireotide is a prescription medicine for serious endocrine disease. It should be started, monitored, changed or stopped only through qualified medical care. For background concepts, see what peptides are and the peptide half-life guide.

Pasireotide At A Glance

How A Multi-Receptor Somatostatin Analog Works

Somatostatin is a natural inhibitory hormone. It tells endocrine cells to release less of several hormones, including growth hormone (GH) and adrenocorticotropic hormone (ACTH). It acts through five receptor subtypes, labeled sst1 through sst5.

Octreotide and lanreotide mostly engage sst2. That works well for many acromegaly patients, because GH-secreting tumors often express sst2. But it leaves a gap. Corticotroph tumor cells in Cushing's disease frequently over-express sst5 rather than sst2, so an sst2-preferential drug has limited grip on ACTH output.

Pasireotide is described as a pan-somatostatin agonist. According to its prescribing information and pharmacology literature, it binds sst1, sst2, sst3 and sst5, with the highest affinity for sst5. In Cushing's disease, binding and activating these receptors inhibits ACTH secretion, which lowers cortisol. In acromegaly, the label notes that sst2 and sst5 binding is relevant to inhibiting GH, and in vivo the LAR depot lowers GH and IGF-1.

Receptor biology also explains a subtle point: pasireotide and octreotide are not simply stronger or weaker versions of each other. Research on sst2A receptor phosphorylation shows they trigger distinct signaling and arrestin patterns, so they are pharmacologically different molecules, not interchangeable doses.

Approval Status And Labeled Uses

Pasireotide is approved, not research-only. The original subcutaneous Signifor product received initial US approval in 2012 for Cushing's disease. The long-acting Signifor LAR depot extended the franchise into acromegaly, and LAR is also used in Cushing's disease.

The labeled populations matter. Pasireotide is generally positioned after surgery or when surgery is not feasible, not as a first move. Cushing's disease and acromegaly are both driven by pituitary tumors, and the surgical and biochemical context shapes whether pasireotide is appropriate at all.

Reference Dose Ranges (Not Recommendations)

These figures come from product labeling and pivotal trials and are listed to characterize how the drug has been studied. They are explicitly not dosing advice, and the route and product differ.

For subcutaneous Signifor in Cushing's disease, the label describes a recommended initial dose of 0.6 mg or 0.9 mg twice daily, with a dosing range of roughly 0.3 mg to 0.9 mg twice daily, titrated to response and tolerability. The twice-daily schedule reflects an effective half-life of about 12 hours reported in healthy volunteers for the subcutaneous form.

For Signifor LAR in acromegaly, the label describes a recommended initial dose of 40 mg by intramuscular injection once every 4 weeks, with the option to increase to a maximum of 60 mg. In Cushing's disease, LAR has been used starting lower and titrated within the labeled range. Because LAR is a depot, its release and practical half-life behavior differ entirely from the subcutaneous product, which is one reason the two formulations are not casually swapped.

What The Evidence Shows, And Its Limits

The pasireotide evidence base is real and label-grade, but it is honest about tradeoffs rather than uniformly glowing.

In Cushing's disease, a 12-month phase 3 randomized study published in the New England Journal of Medicine assigned adults to subcutaneous pasireotide 600 mcg or 900 mcg twice daily. Urinary free cortisol normalized in a minority of patients, more often in the higher-dose group, and the effect was largely seen in those with less extreme baseline cortisol. That is meaningful, but it also means pasireotide does not normalize cortisol in everyone, and patient selection matters.

In acromegaly, a phase 3 study compared pasireotide LAR with octreotide LAR in patients not previously treated medically, and pasireotide LAR achieved biochemical control (GH and IGF-1 targets) in a larger share of patients. The PAOLA trial then tested pasireotide LAR against continued octreotide or lanreotide in patients already inadequately controlled on those drugs, and pasireotide LAR was superior for biochemical control. Extension data reported maintained GH and IGF-1 suppression over longer follow-up.

The consistent caveat across these trials is metabolic. Reviewers and the labels repeatedly note that the improved hormonal control comes with a clear increase in hyperglycemia compared with older somatostatin analogs. So the evidence supports efficacy in defined populations while flagging a predictable cost that has to be managed, not ignored.

Safety Issues

Pasireotide safety follows directly from somatostatin biology. Somatostatin also suppresses insulin and incretin hormones, so a potent multi-receptor analog can disturb glucose metabolism.

Pasireotide can also cause diarrhea, nausea, abdominal pain, injection-site reactions, fatigue and headache among other effects. The hyperglycemia signal is the one that distinguishes it most sharply from older agents and is the reason glucose monitoring is built into its labeling.

How To Evaluate A Pasireotide Claim

Because pasireotide is a real drug, online claims sometimes borrow its credibility for unrelated purposes. A few questions help.

First, which product and route is being discussed: subcutaneous Signifor or the intramuscular Signifor LAR depot? They differ in dosing, schedule and behavior.

Second, what is the indication: Cushing's disease, acromegaly or something off-label? The labeled populations are specific and surgery-related.

Third, does the source mention hyperglycemia? Any honest description of pasireotide has to. If a claim presents only benefits and omits the glucose risk, it is incomplete.

Fourth, is label-grade evidence being used to imply unmonitored or wellness use? That is a red flag. Pasireotide requires baseline and ongoing glucose, ECG, liver and electrolyte monitoring.

For contrast, other peptide-based prescription therapies in gastroenterology and related fields, such as linaclotide, teduglutide and icatibant, each have their own narrow labels and monitoring needs. Like pasireotide, they are not generic "peptide therapy."

Bottom Line

Pasireotide is a genuine peptide medicine with FDA labels and phase 3 evidence in Cushing's disease and acromegaly. Its multi-receptor profile, especially its high affinity for somatostatin receptor subtype 5, lets it suppress ACTH and lower GH and IGF-1 in settings where subtype-2-preferential analogs like octreotide underperform.

That same potency carries a cost. Hyperglycemia is frequent and can be severe, and the drug also demands attention to QT, liver, gallbladder, cortisol and electrolyte status. Pasireotide is best understood as a specialist, monitored treatment for defined pituitary disease, chosen by an endocrinologist after surgical options are weighed, not as a generic somatostatin or wellness peptide.

References

1. DailyMed. SIGNIFOR LAR (pasireotide) for injectable suspension prescribing information.

2. DailyMed. SIGNIFOR (pasireotide) injection prescribing information.

3. US FDA. SIGNIFOR (pasireotide diaspartate) injection label, 2012.

4. European Medicines Agency. Signifor (pasireotide) product information.

5. Colao A, et al. A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. N Engl J Med 2012.

6. PubMed. A 12-month phase 3 study of pasireotide in Cushing's disease (citation).

7. Gadelha MR, et al. Pasireotide versus continued octreotide or lanreotide in inadequately controlled acromegaly (PAOLA): a randomised phase 3 trial. Lancet Diabetes Endocrinol 2014.

8. Sheppard M, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in acromegaly up to 25 months: blinded extension of a phase 3 study.

9. van der Hoek J, et al. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

10. Golor G, et al. A first-in-man study of the safety, tolerability and pharmacokinetics of pasireotide (SOM230) in healthy volunteers.

11. McKeage K. Pasireotide in Acromegaly: A Review. Drugs 2015.